Allogeneic UCB-derived CAR-T for SLE

NCT07274059 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

SLE - Systemic Lupus Erythematosus

Interventions

DRUG: allogeneic umbilical cord blood-derived CAR-T targeting CD19 and BCMA

Sponsor

Chengdu Ucello Biotechnology Co., Ltd.

Collaborators

[object Object]
[object Object]